CONSORT Med PLC/S (OTCMKTS:CSRMY) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Saturday.
Separately, Zacks Investment Research lowered CONSORT Med PLC/S from a “hold” rating to a “sell” rating in a research note on Wednesday, December 5th.
CONSORT Med PLC/S stock opened at $10.80 on Friday. The firm has a market capitalization of $532.28 million, a P/E ratio of 12.56 and a beta of 0.01. CONSORT Med PLC/S has a 52 week low of $13.25 and a 52 week high of $16.65.
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.
See Also: How Investors Use a Balance Sheet
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for CONSORT Med PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONSORT Med PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.